Bank of America’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.4M | Buy |
404,067
+138,800
| +52% | +$7.71M | ﹤0.01% | 2318 |
|
|
2026
Q1 | $15.4M | Buy |
265,267
+43,899
| +20% | +$2.02M | ﹤0.01% | 2600 |
|
|
2025
Q4 | $9.92M | Buy |
221,368
+22,262
| +11% | +$935K | ﹤0.01% | 2861 |
|
|
2025
Q3 | $7.99M | Sell |
199,106
-159,326
| -44% | -$5.61M | ﹤0.01% | 3525 |
|
|
2025
Q2 | $11.2M | Buy |
358,432
+221,863
| +162% | +$7.24M | ﹤0.01% | 3139 |
|
|
2025
Q1 | $4.58M | Buy |
136,569
+29,663
| +28% | +$1.13M | ﹤0.01% | 3893 |
|
|
2024
Q4 | $4.19M | Sell |
106,906
-20,550
| -16% | -$850K | ﹤0.01% | 3756 |
|
|
2024
Q3 | $5.02M | Sell |
127,456
-14,876
| -10% | -$600K | ﹤0.01% | 3728 |
|
|
2024
Q2 | $5.55M | Sell |
142,332
-14,772
| -9% | -$590K | ﹤0.01% | 3523 |
|
|
2024
Q1 | $6.76M | Buy |
157,104
+23,692
| +18% | +$1.09M | ﹤0.01% | 3353 |
|
|
2023
Q4 | $6.14M | Buy |
133,412
+9,445
| +8% | +$334K | ﹤0.01% | 3374 |
|
|
2023
Q3 | $4.23M | Sell |
123,967
-35,409
| -22% | -$1.32M | ﹤0.01% | 3555 |
|
|
2023
Q2 | $6.14M | Buy |
159,376
+25,265
| +19% | +$1M | ﹤0.01% | 3201 |
|
|
2023
Q1 | $4.8M | Buy |
134,111
+45,363
| +51% | +$1.68M | ﹤0.01% | 3577 |
|
|
2022
Q4 | $3.5M | Buy |
88,748
+61,753
| +229% | +$2.25M | ﹤0.01% | 3746 |
|
|
2022
Q3 | $974K | Sell |
26,995
-9,660
| -26% | -$347K | ﹤0.01% | 4921 |
|
|
2022
Q2 | $1.11M | Buy |
36,655
+30,376
| +484% | +$919K | ﹤0.01% | 4821 |
|
|
2022
Q1 | $192K | Sell |
6,279
-36,519
| -85% | -$1.09M | ﹤0.01% | 6496 |
|
|
2021
Q4 | $1.34M | Buy |
42,798
+28,411
| +197% | +$849K | ﹤0.01% | 4967 |
|
|
2021
Q3 | $220K | Buy |
14,387
+7,408
| +106% | +$129K | ﹤0.01% | 6237 |
|
|
2021
Q2 | $130K | Sell |
6,979
-10,293
| -60% | -$190K | ﹤0.01% | 6364 |
|
|
2021
Q1 | $309K | Buy |
17,272
+14,414
| +504% | +$244K | ﹤0.01% | 5728 |
|
|
2020
Q4 | $44K | Sell |
2,858
-485
| -15% | -$5.67K | ﹤0.01% | 6375 |
|
|
2020
Q3 | $37K | Sell |
3,343
-187
| -5% | -$2.2K | ﹤0.01% | 6120 |
|
|
2020
Q2 | $44K | Buy |
+3,530
| New | +$44.9K | ﹤0.01% | 6043 |
|
|
2020
Q1 | – | Sell |
-2,618
| Closed | -$34K | – | 7287 |
|
|
2019
Q4 | $34K | Buy |
+2,618
| New | +$27.5K | ﹤0.01% | 6371 |
|
|
2019
Q3 | – | Sell |
-53
| Closed | – | – | 7539 |
|
|
2019
Q2 | $0 | Sell |
53
-29
| -35% | -$277 | ﹤0.01% | 7438 |
|
|
2019
Q1 | $1K | Sell |
82
-1,247
| -94% | -$10.6K | ﹤0.01% | 7006 |
|
|
2018
Q4 | $8K | Buy |
+1,329
| New | +$11.8K | ﹤0.01% | 6681 |
|
|
2015
Q4 | – | Sell |
-2,182
| Closed | -$18K | – | 7499 |
|
|
2015
Q3 | $18K | Buy |
+2,182
| New | +$21.7K | ﹤0.01% | 6347 |
|
|
2015
Q2 | – | Sell |
-3,033
| Closed | -$51K | – | 7428 |
|
|
2015
Q1 | $51K | Hold |
3,033
| – | – | ﹤0.01% | 5650 |
|
|
2014
Q4 | $60K | Buy |
+3,033
| New | +$44.5K | ﹤0.01% | 6233 |
|
Other funds holding XENE
ACA
PCH
DCM
JT
Bank of America's XENE Position: Q2 2026 in Review
Bank of America increased its Xenon Pharmaceuticals (XENE) stake by 52% in Q2 2026, buying an estimated $7.71M and bringing the position to 404,067 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2318.
Bank of America first reported a position in XENE in Q4 2014 and has held it in 32 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.
- Bank of America held 404,067 shares of Xenon Pharmaceuticals worth $24.4M as of Q2 2026.
- Bank of America bought 138,800 Xenon Pharmaceuticals shares in Q2 2026, an estimated $7.71M.
- Xenon Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2318 holding.
- Bank of America first reported a position in Xenon Pharmaceuticals in Q4 2014 and has held it in 32 quarters since.
- 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.